Product image of Linezolid Accordpharma (Linezolid) supplied by GNH India

Linezolid Accordpharma

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Accordpharma (Linezolid)

Linezolid, the active ingredient in Linezolid Accordpharma, is an oxazolidinone presented as an intravenous formulation for the treatment of serious Gram‑positive bacterial infections, including methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE), in adult patients.

GNH India supplies Linezolid Accordpharma as a licensed, EU‑origin, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this antibiotic for qualified healthcare providers.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linezolid is an oxazolidinone antibiotic used to treat infections caused by resistant Gram‑positive bacteria.

  • Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective for skin, soft‑tissue and pneumonia caused by MRSA.
  • Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative option for VRE bloodstream and urinary infections.
  • Community‑acquired and hospital‑acquired pneumonia: active against typical pathogens, reducing disease severity.
  • Skin and soft tissue infections: treats complicated infections where other agents may fail.

How It Works

  • Linezolid binds to the 50S subunit of bacterial ribosomes, preventing the formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth by blocking translation of essential proteins, leading to a bacteriostatic effect against susceptible Gram‑positive organisms.

Side Effects

Linezolid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea: transient gastrointestinal upset.
  • Diarrhea: mild to moderate loose stools.
  • Headache: occasional tension‑type headache.
  • Vomiting: occasional episodes.
  • Metallic taste: transient dysgeusia.
  • Myelosuppression (early): mild decrease in blood cell counts.

Serious or Rare Side Effects

  • Thrombocytopenia: significant drop in platelet count.
  • Anemia: reduction in red blood cell levels.
  • Peripheral neuropathy: numbness or tingling in extremities.
  • Optic neuropathy: visual disturbances, potentially irreversible.
  • Serotonin syndrome: risk when combined with serotonergic agents.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.

Precautions & Warnings

When prescribing Linezolid, clinicians should consider several safety measures.

  • Renal impairment: monitor renal function and adjust therapy if needed.
  • Hepatic impairment: assess liver enzymes periodically.
  • Concomitant serotonergic agents: avoid due to risk of serotonin syndrome.
  • Myelosuppression: perform regular complete blood counts.
  • Pregnancy and lactation: use only if benefits outweigh potential risks; safety not established.
  • Store at below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

  • Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome.
  • Monoamine oxidase inhibitors (MAOIs): increased serotonergic effects.
  • Rifampicin: reduces linezolid plasma concentrations, potentially compromising efficacy.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect; monitor INR.
  • Cyclosporine: possible increased toxicity; observe renal function.
  • Theophylline: may increase plasma concentrations; monitor for toxicity.

Frequently Asked Questions

Linezolid Accordpharma is an intravenous oxazolidinone antibiotic indicated for the treatment of serious Gram‑positive infections such as methicillin‑resistant Staphylococcus aureus (MRSA), vancomycin‑resistant Enterococcus (VRE), community‑acquired and hospital‑acquired pneumonia, and complicated skin and soft‑tissue infections.

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and preventing formation of the initiation complex. This blocks translation of essential proteins, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms.

The dosage and duration of therapy for Linezolid Accordpharma are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. No fixed regimen is provided here.

Safety data for linezolid in pregnancy and lactation are limited. It should be used only when the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Linezolid offers oral and intravenous options and is active against many resistant Gram‑positive strains, whereas vancomycin, a glycopeptide, is limited to intravenous use and may be less effective against certain VRE isolates. Linezolid also avoids the nephrotoxicity associated with vancomycin but requires monitoring for hematologic toxicity.

Store the product at temperatures below 25 °C, in its original packaging, protected from moisture and light. Do not freeze. Follow standard aseptic techniques when preparing the intravenous solution, and discard any solution that appears discolored or contaminated.

Linezolid Accordpharma is given by intravenous infusion. The infusion is prepared according to the manufacturer’s instructions and administered over a period specified by the prescriber, typically 30 minutes to 1 hour, using sterile equipment.

Serious adverse events include thrombocytopenia, anemia, peripheral or optic neuropathy, and serotonin syndrome when combined with serotonergic drugs. Patients should be monitored regularly for blood‑cell counts, visual changes, and signs of serotonin excess.

Linezolid should be avoided in patients with known hypersensitivity to linezolid or any component of the formulation. Caution is advised in individuals taking serotonergic agents, MAO inhibitors, or those with pre‑existing severe myelosuppression, as the drug may exacerbate these conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linezolid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT